{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:49:45Z","timestamp":1783662585165,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001878"],"award-info":[{"award-number":["UL1TR001878"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:23:41Z","timestamp":1716510221000},"page":"758-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of lumacaftor\/ivacaftor on nutrition and growth in modulator-na\u00efve children over 24 weeks"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-3002","authenticated-orcid":false,"given":"Alyssa","family":"Tindall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3290-7355","authenticated-orcid":false,"given":"Rosara","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8322-9655","authenticated-orcid":false,"given":"Asim","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia A","family":"Stallings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcf.2024.05.005_bib0001","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/13993003.01444-2015","article-title":"Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation","volume":"47","author":"Dilokthornsakul","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jcf.2024.05.005_bib0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jcf.2019.12.006","article-title":"Lumacaftor\/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease","volume":"19","author":"Tong","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2024.05.005_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071527","article-title":"Real-World outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"Duckers","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.05.005_bib0004","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17476348.2019.1602040","article-title":"Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis","volume":"13","author":"Cheng","year":"2019","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.05.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0016-2020","article-title":"The era of CFTR modulators: improvements made and remaining challenges","volume":"16","author":"Cuevas-Ocana","year":"2020","journal-title":"Breathe"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.005_bib0006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.05.005_bib0007","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jcf.2014.01.009","article-title":"Effect of a dietary intervention on growth and energy expenditure in children with cystic fibrosis","volume":"13","author":"Groleau","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.05.005_bib0008","first-page":"5","article-title":"Predicting basal metabolic rate, new standards and review of previous work","volume":"39","author":"Schofield","year":"1985","journal-title":"Hum Nutr Clin Nutr"},{"key":"10.1016\/j.jcf.2024.05.005_bib0009","first-page":"312","year":"2006","journal-title":"Ebrary,inc.WHO child growth standards length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age : methods and development"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.005_bib0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0884533615591604","article-title":"Nutrition management of cystic fibrosis in the 21st century","volume":"30","author":"Schindler","year":"2015","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.jcf.2024.05.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.04.010","article-title":"Changes in nutrition and growth status in young children in the first 12 weeks of ivacaftor therapy","author":"Tindall","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.05.005_bib0012","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MPG.0000000000003173","article-title":"Gastrointestinal factors associated with hospitalization in infants with cystic fibrosis: results from the baby observational and nutrition study","volume":"73","author":"Sathe","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.005_bib0013","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12876-022-02553-x","article-title":"The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients","volume":"22","author":"Imanzadeh","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.jcf.2024.05.005_bib0014","first-page":"514","article-title":"Fecal calprotectin in the pediatric population: a 2020 update","volume":"72","author":"Cisar","year":"2020","journal-title":"Minerva Pediatr"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.005_bib0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MPG.0000000000001544","article-title":"Fecal calprotectin in cystic fibrosis and its relation to disease parameters: a longitudinal analysis for 12 years","volume":"65","author":"Ellemunter","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2024.05.005_bib0016","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcf.2017.03.010","article-title":"Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children","volume":"16","author":"Garg","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.05.005_bib0017","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ppul.23972","article-title":"Metabolomic responses to lumacaftor\/ivacaftor in cystic fibrosis","volume":"53","author":"Kopp","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.05.005_bib0018","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcf.2018.09.001","article-title":"IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation","volume":"18","author":"van de Peppel","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.05.005_bib0019","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-3476(62)80065-1","article-title":"The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas","volume":"60","author":"Kuo","year":"1962","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2024.05.005_bib0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1542\/peds.2004-2832","article-title":"Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis","volume":"117","author":"Shoff","year":"2006","journal-title":"Pediatrics"},{"issue":"1 Pt 1","key":"10.1016\/j.jcf.2024.05.005_bib0021","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1542\/peds.105.1.53","article-title":"Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening","volume":"105","author":"Lai","year":"2000","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jcf.2024.05.005_bib0022","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ajcn\/54.3.578","article-title":"Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention","volume":"54","author":"Marcus","year":"1991","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jcf.2024.05.005_bib0023","series-title":"Nutrition in cystic fibrosis: a guide for clinicians","article-title":"Dietary fat and fat metabolism in cystic fibrosis","author":"Maqbool","year":"2016"},{"issue":"5","key":"10.1016\/j.jcf.2024.05.005_bib0024","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1067\/mpd.2001.118890","article-title":"Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis","volume":"139","author":"Strandvik","year":"2001","journal-title":"J Pediatr"},{"issue":"23","key":"10.1016\/j.jcf.2024.05.005_bib0025","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.83.23.9202","article-title":"Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect","volume":"83","author":"Carlstedt-Duke","year":"1986","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1016\/j.jcf.2024.05.005_bib0026","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/MPG.0b013e3180690da9","article-title":"Polyunsaturated fatty acids in cystic fibrosis are related to nutrition and clinical expression of the disease","volume":"45","author":"Walkowiak","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2024.05.005_bib0027","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/MPG.0b013e31817fb76b","article-title":"Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis","volume":"47","author":"Maqbool","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.005_bib0028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcf.2016.07.006","article-title":"The effects of ivacaftor on CF fatty acid metabolism: an analysis from the GOAL study","volume":"16","author":"O'Connor","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.05.005_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.619442","article-title":"CFTR correctors and antioxidants partially normalize lipid imbalance but not abnormal basal inflammatory cytokine profile in cf bronchial epithelial cells","volume":"12","author":"Veltman","year":"2021","journal-title":"Front Physiol"},{"issue":"7\u20138","key":"10.1016\/j.jcf.2024.05.005_bib0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.bbalip.2011.05.002","article-title":"Increased Delta5- and Delta6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis","volume":"1811","author":"Njoroge","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.jcf.2024.05.005_bib0031","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/23808993.2016.1175299","article-title":"Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation","volume":"1","author":"Cholon","year":"2016","journal-title":"Expert Rev Precis Med Drug Dev"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:10:21Z","timestamp":1783019421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324000687"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of lumacaftor\/ivacaftor on nutrition and growth in modulator-na\u00efve children over 24 weeks","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}